Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
J. G. Berdeja(Sarah Cannon), Aaron T. Gerds(Cleveland Clinic), Richard A. Walgren(Eli Lilly (United States)), Celine Pitou(Eli Lilly (United States)), Maria R. Baer(University of Maryland, Baltimore), Giovanni Martinelli(University of Bologna), Oday Hamid(Eli Lilly (United States)), P.L. Li(Eli Lilly (United States)), Donald P. Quick, Francesca Palandri(Istituto Oncologico Romagnolo), Amit Verma(M.J.P. Rohilkhand University), Jean‐Jacques Kiladjian(Délégation Paris 5)
Cited by 50
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k